Search

everythinglearnresearchcommunity

for

Search:↓

DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Severe alopecia areata may increase the risk of heart-related diseases.

People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.

Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.

Men with advanced liver disease and high oestrone and low testosterone levels have worse health outcomes.

Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.

Tph cells are linked to the severity of systemic lupus erythematosus.

Alopecia areata treatments often don't lead to lasting improvement.

Higher IL-21 levels may help predict alopecia areata activity.

The CLASI is useful but needs revision to accurately assess all cutaneous lupus erythematosus subtypes.

Higher EGF levels are linked to more severe alopecia areata.

Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.

Kids with alopecia areata had lower vitamin D levels than healthy kids.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Alopecia areata and androgenetic alopecia affect quality of life similarly.

Premature graying of hair is often linked with other health issues, but treatment with biotin, zinc, and calcium pantothenate is not very effective.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

Wigs significantly improve the well-being of people with severe hair loss.

COVID-19 doesn't make alopecia areata worse.

People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.

Certain hair and scalp features can predict the severity of alopecia areata.

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Traction alopecia is more common in African women than girls, especially when traction is applied to chemically relaxed hair; avoiding such hairstyles may reduce the risk.